WHIPPANY, NJ, USA I June 03, 2025 I Bayer announced today that the U.S. Food and Drug Administration (FDA) has approved its oral androgen receptor inhibitor ...

SOUTH SAN FRANCISCO, CA, USA I June 03, 2025 I TRex Bio, Inc. (“TRexBio”), a clinical-stage biotechnology company decoding human tissue immune biology to ...

SAN DIEGO, CA, USA I June 03, 2025 I Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology ...

Ongoing Phase 2 study enrolling 102 patients in the U.S. and South Korea, with more than 50% of participants identified as Asian ...

Phase 1 trial demonstrates encouraging clinical activity of investigational immunotherapy for relapsed or refractory multiple myeloma ...

LUND, Sweden and INDIANAPOLIS, IN, USA I June 3, 2025 I Camurus (NASDAQ STO: CAMX) and Eli Lilly and Company ("Lilly") have entered a collaboration and ...

HONG KONG, China I June 3, 2025 I Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that denifanstat (ASC40), a first-in-class, once-daily oral ...

BASEL, Switzerland I June 04, 2025 I Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission (EC) has approved a label extension for ...

BALLERUP, Denmark I June 03, 2025 I LEO Pharma A/S, a global leader in medical dermatology, today announced the initiation of the phase 2a proof-of-concept ...

LUXEMBOURG & LEIDEN, The Netherlands I June 03, 2025 I The European Investment Bank (EIB) and Dutch clinical-stage biotechnology company Leyden ...

STAT6 is a key transcription factor within the IL4/IL13 signaling pathways which act as drivers of inflammation in allergic conditions ...

AMT-130 has been granted the FDA’s Regenerative Medicine Advance Therapy (RMAT) designation and Breakthrough Therapy designation, the first therapy for Huntington’s disease to receive an RMAT ...